Human stem cell-based cell replacement therapy for Parkinson’s disease:Enhancing the survival of postmitotic dopamine neuron graftsOA
Parkinson’s disease(PD)is the second most common neurodegenerative disorder.The progressive degeneration of dopamine(DA)producing neurons in the midbrain is the pathological hallmark,which leads to debilitating motor symptoms,including tremors,rigidity,and bradykinesia.Drug treatments,such as levodopa,provide symptomatic relief.However,they do not halt disease progression,and their effectiveness diminishes over time(reviewed in Poewe et al.,2017).
Tae Wan Kim
Department of Interdisciplinary Engineering,DGIST,Daegu,Republic of Korea
医药卫生
neuronal survivalcell replacement therapydopamine neuronshuman stem cellsbradykinesiadrug treatmentssuchParkinsons diseaseneurodegenerative disordertheparkinson s disease pd
《Neural Regeneration Research》 2026 (2)
P.689-690,2
supported by the DGIST start-up funds from the Ministry of Science and ICT(2024010330)a National Research Foundation of Korea(NRF)grant funded by the Korea Government(MSIT)(No.RS-2024-00351442)(to TWK).
评论